Alzheimer's disease, a devastating neurodegenerative condition that affects millions of people worldwide, may have found a ...

DelveInsight’s, “Peripheral Arterial Disease Pipeline Insight 2024” report provides comprehensive insights about 18+ ...

MONCYTE Health, a diagnostics company based in Helsinki, has raised €1 million in a seed funding round to advance its ...

For an exclusive license to the preclinical Lp(a) disruptor, AstraZeneca is paying CSPC Pharmaceutical Group $100 million ...

AstraZeneca (AZ) has entered into an exclusive licence agreement worth over $1.9bn to advance CSPC Pharmaceutical Group’s pre-clinical lipid-lowering therapy, strengthening the Anglo-Swedish drugmaker ...

Obicetrapib was tested as a monotherapy and in combination with lipid-lowering medications like statins. The topline results from the pivotal BROOKLYN trial were announced in July 2024.

A number of prescription drugs are available to help reduce LDL cholesterol and triglyceride levels. However, many health-conscious people would prefer to improve their lipid levels without resorting ...

This study aimed to assess the causal relationship between genetically proxied lipid-lowering drugs and skin cancers and psoriasis. Methods: Two-sample Mendelian randomization (MR) analysis was ...

Background: The escalating global economic burden of ischemic stroke poses a significant public health challenge amid global aging trends. The broad therapeutic efficacy of new antidiabetic drugs may ...

Based on a 40 mg oral dose with the exception of fluvastatin extended release (80 mg) and pitavastatin 2 mg.

MONCYTE Health diagnostics, developing proprietary technology to optimize treatment and prevention of cardiovascular disease, has closed a EUR 1 million seed ...

October 2024 AstraZeneca strengthens its cardiovascular pipeline with agreement for a pre-clinical novel lipid-lowering therapyAstraZeneca has entered into an exclusive license agreement with CSPC Pha ...